As your expert extension, Evestia Clinical provides comprehensive and focused expertise across the spectrum of oncology clinical trials.
We understand the critical importance of advancing innovative cancer therapies and are deeply committed to supporting biotech companies in this vital endeavor.
Our experienced teams bring a wealth of knowledge across a multitude of oncology indications, leveraging insights gained from our extensive work with complex trials and our understanding of the unique challenges within this therapeutic landscape.
We emphasize a partnership approach, working closely with you as a seamless part of your team to navigate the intricacies of each trial phase. Our commitment extends to incorporating a patient-centric perspective throughout the clinical trial lifecycle, recognizing the human impact of the research we conduct.
Our rare disease forum/patient advocacy group that will further enhances our understanding of patient needs and inform our strategies in rare oncology indications and beyond.
Our oncology experience spans both adult and pediatric populations, with deep expertise built from participation in more than 300 studies across a wide range of solid tumors and hematologic malignancies — including breast, lung, colorectal, pancreatic, prostate, ovarian, GBM, multiple myeloma, leukemia, and rare cancers like osteosarcoma and Ewing sarcoma.
Today, 63% of our team brings oncology-specific experience to their work. We also offer focused support in cell and gene therapies, drawing on collective experience across 50+ studies and a growing team with direct expertise in these advanced modalities. This breadth of experience allows us to tailor strategies to the unique demands of your program — whether in a high-prevalence indication or a rare, complex therapeutic space.
